Actionnariat et activité des initiés pour CytomX Therapeutics, Inc. (CTMX): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $2.77 |
| Capitalisation | $602M |
| Bourse | NASDAQ |
| Pays | US |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-08-03 | Carvajal Alejandra | A-Award | 450,000 | $1.4M |
| 2026-08-03 | Carvajal Alejandra | A-Award | 100,000 | |
| 2026-08-03 | Carvajal Alejandra | |||
| 2026-07-24 | Fuchs Charles S. | A-Award | 118,000 | $382K |
| 2026-07-24 | Fuchs Charles S. | |||
| 2026-06-17 | Su Zhen | A-Award | 59,000 | $175K |
| 2026-06-17 | Young Matthew P. | A-Award | 59,000 | $175K |
| 2026-06-17 | Mohindru Mani | A-Award | 59,000 | $175K |
| 2026-06-17 | Meyers James R | A-Award | 59,000 | $175K |
| 2026-06-17 | Gilbert Halley E | A-Award | 59,000 | $175K |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $104.6M | $177.5M | $247.6M | $188.4M | $191.9M | $205.5M | $193.7M | $17.2M | $38.1M | $12.7M |
| Placements à Court Terme | $77.3M | $196.6M | $188.6M | $107.7M | $124.3M | $99.7M | 0 | $157.3M | $62.6M | $124.4M |
| Créances | $2.3M | $10.1M | $97000 | $13000 | $798000 | $790000 | $36.0M | $3.4M | $3.1M | $2.0M |
| Stocks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $188.1M | $388.6M | $445.5M | $303.3M | $324.0M | $310.3M | $237.1M | $182.9M | $107.3M | $143.9M |
| Immobilisations Corporelles | $4.4M | $4.2M | $6.9M | $32.8M | $29.4M | $25.3M | $21.0M | $16.2M | $10.6M | $4.7M |
| Goodwill | $949000 | $949000 | $949000 | $949000 | $949000 | $949000 | $949000 | $949000 | $949000 | $949000 |
| Actifs Incorporels | $1.8M | $1.6M | $1.5M | $1.3M | $1.2M | $1.0M | $875000 | $729000 | $583000 | $438000 |
| Actifs Totaux | $199.1M | $397.6M | $457.1M | $341.3M | $358.7M | $339.4M | $260.9M | $201.8M | $120.5M | $151.6M |
| Dettes Fournisseurs | $6.6M | $4.2M | $5.1M | $4.2M | $3.0M | $2.8M | $2.8M | $1.5M | $1.1M | $1.3M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $4.2M |
| Passifs Courants | $35.8M | $61.1M | $97.9M | $85.6M | $68.1M | $77.9M | $152.6M | $155.9M | $85.8M | $46.6M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Totaux | $120.6M | $327.7M | $326.2M | $290.2M | $366.4M | $339.9M | $346.6M | $249.2M | $121.0M | $52.6M |
| Réserves | -$176.4M | -$219.5M | -$315.0M | -$417.2M | -$507.7M | -$623.6M | -$722.9M | -$723.4M | -$691.6M | -$711.9M |
| Capitaux Propres | $78.5M | $69.9M | $130.9M | $51.1M | -$7.8M | -$459000 | -$85.8M | -$47.4M | -$456000 | $99.0M |
| Dette Totale | 0 | 0 | 0 | $27.7M | $24.9M | $21.7M | $18.1M | $14.0M | $9.4M | $4.2M |
| Dette Nette | -$181.9M | -$374.1M | -$436.1M | -$268.5M | -$291.2M | -$283.6M | -$175.6M | -$160.5M | -$91.2M | -$132.8M |
| Fonds de Roulement | $152.4M | $327.5M | $347.6M | $217.7M | $255.9M | $232.4M | $84.5M | $27.0M | $21.5M | $97.3M |
Santé financière
| Dette / Capitaux propres | 0.02 |
| Ratio de liquidité | 9.36 |
Rentabilité
| Rentabilité des capitaux propres | -38.46% |
| Rentabilité du capital investi | -25.42% |
| Rentabilité des actifs | -20.89% |
| Marge brute | 98.63% |
| Marge opérationnelle | -476.19% |
| Marge nette | -435.21% |
Entreprises liées: ATXS · AVBP · AVXL · DNA · ERAS · IOVA · MBX
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de CTMX: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions